Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
November 25 2019 - 4:05PM
Myovant Sciences (NYSE: MYOV), a healthcare company focused on
developing innovative treatments for women's health and prostate
cancer, today announced that Lynn Seely, M.D., Myovant’s President
and CEO, will present at the Evercore ISI 2nd Annual HealthCONx
Conference on Tuesday, December 3, 2019 at 10:35 a.m. Eastern Time
in Boston, MA.
A live webcast of the presentation will be accessible on the
Events page under the Investors & Media section of the Myovant
website at www.myovant.com. Please connect to the company's website
at least 15 minutes prior to the presentation to ensure adequate
time for any software download that may be required to listen to
the webcast. A replay of the webcast will be available at the same
location for 30 days following the conference.
About Myovant Sciences Myovant
Sciences aspires to be the leading healthcare company focused
on innovative treatments for women’s health and prostate cancer.
The company’s lead product candidate is relugolix, a once-daily,
oral GnRH receptor antagonist. The company has three
late-stage clinical programs for relugolix in uterine fibroids,
endometriosis, and prostate cancer. The company is also developing
MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has
completed a Phase 2a study for the treatment of female infertility
as part of assisted reproduction. Takeda Pharmaceuticals
International AG, a subsidiary of Takeda Pharmaceutical Company
Limited, granted the company an exclusive, worldwide
license to develop and commercialize relugolix (excluding Japan and
certain other Asian countries) and an exclusive license to develop
and commercialize MVT-602 in all countries worldwide. For more
information, please visit the company’s website
at www.myovant.com. Follow @Myovant on Twitter and
LinkedIn.
Investor Contact: Frank Karbe Chief Financial
Officer Myovant Sciences, Inc. investors@myovant.com
Media Contact:Albert Liao Director,
Corporate CommunicationsMyovant Sciences, Inc.
media@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024